Half of patients discontinue treatment within a year

GLP1 receptor agonists have revolutionized the treatment of obesity, but their effectiveness depends on long-term and continuous use. However, data from Danish health registries presented at EASD 2025 show that up to 52% of adults without diabetes discontinued their GLP1 RA therapy within 12 months of starting.